Merit Medical Systems chief HR officer sells $1.38 million in stock

Published 04/03/2025, 02:26
Merit Medical Systems chief HR officer sells $1.38 million in stock

SOUTH JORDAN, Utah—Voigt Michel James, the Chief Human Resources Officer at Merit Medical Systems Inc. (NASDAQ:MMSI), a $6.08 billion medical device company whose stock has gained nearly 35% over the past year, recently sold a significant portion of the company’s common stock. According to InvestingPro data, the company maintains strong financial health with a "GREAT" overall rating. According to a Form 4 filing with the Securities and Exchange Commission, James sold 13,809 shares at an average price of $99.68 per share, amounting to a total of $1.38 million.

In addition to the stock sale, James engaged in other transactions that affected his holdings. On February 27, he acquired 11,533 shares of common stock through performance stock units, which were issued after meeting certain conditions set by the company’s Compensation and Talent Development Committee. These shares were acquired at no cost.

Further transactions on February 28 included the acquisition of restricted stock units and the exercise of stock options. James acquired 5,488 restricted stock units, which vest in three annual installments, and exercised options to acquire 13,809 shares at prices ranging from $56.25 to $70.58 per share. These transactions resulted in a total acquisition value of $848,122.

Additionally, James surrendered 4,530 shares to the company to cover payroll taxes, a transaction valued at $446,205 based on a price of $98.50 per share.

Following these transactions, James holds 22,399 shares of Merit Medical Systems common stock. The stock, which currently trades at $103.03, appears overvalued according to InvestingPro analysis, despite the company’s solid fundamentals including a healthy current ratio of 4.27 and moderate debt levels. Investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks including MMSI.

In other recent news, Merit Medical Systems, Inc. reported its fourth-quarter 2024 earnings, showcasing strong financial performance. The company reported earnings per share (EPS) of $0.93, surpassing the forecast of $0.82, and revenue of $355.2 million, exceeding expectations of $346.76 million. This performance reflects a 9% year-over-year increase in total revenue and a significant 30% growth in non-GAAP operating profit. Merit Medical (TASE:BLWV)’s gross margin improved by approximately 300 basis points year-over-year, marking a record for the company.

The company also highlighted a 67% increase in free cash flow, totaling $185 million for 2024. Looking forward, Merit Medical provided guidance for 2025, projecting revenue growth of 8-10% and non-GAAP EPS in the range of $3.58 to $3.70. Recent acquisitions, including Cook Medical and EndoGastric Solutions, are performing beyond expectations, contributing to the company’s robust performance.

Analyst firms have adjusted their price targets for Merit Medical, with Oppenheimer and Needham both lowering their targets to $116, while Raymond (NSE:RYMD) James raised its target to the same figure, maintaining an Outperform rating. These adjustments come despite Merit Medical’s optimistic guidance and strong historical growth, with analysts generally expressing confidence in the company’s ability to sustain its growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.